Evolution of Continuous Chromatography: Moving Beyond Chiral Separations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evolution of Continuous Chromatography: Moving Beyond Chiral Separations
The author presents recent developments in simulated moving-bed chromatography in production of active pharmaceutical ingredients and intermediates. This article is part of a special issue on APIs.


Pharmaceutical Technology
pp. s22-s27


Figure 3: Comparison between traditional four-zone simulated moving-bed (SMB) and the modified SMB system for separations with large selectivity or increasing retention time. (FIGURE IS COURTESY OF THE AUTHOR)
SMB modifications for increased throughput. SMB provides a significant advantage over batch chromatography when the selectivity of the separation is rather low. In the case of high selectivity, batch chromatography may outperform SMB because of flow and operating pressure constraints. In an SMB unit, the flow rate in the first zone of columns pushes out the most retained product. For a long retention time, it takes a high flow rate to push everything out of the column before the column switch occurs. Because all the zones of the SMB are connected, if one zone is operated at a very high flow rate, then the other zones must be operated at a lower flow rate. This zone manipulation is necessary to manage operations below the maximum operating pressure of the system. As a result, the production rate is reduced. AFC developed a simple modification to the process (see Figure 3) that alleviates the pressure constraint by decoupling the first zone of the SMB from the other zones of the SMB unit (12). This additional zone allows for a rapid wash of the column with the mobile phase at maximum operating pressure without affecting the pressure in the other zone. As a result, the rest of the separation can be conducted at a higher flow rate and therefore at a higher throughput.

SMB for chiral separations and impurity removal. Ideally, racemic feeds only contain the two enantiomers. Unfortunately, in most cases, a few impurities that are closely related to the product also are present in the mixture. These impurities are usually either leftover starting material or side products from previous reactions. In either case, they might be difficult to remove during downstream processing without sacrificing yield. The chiral SMB separation can potentially be used to purify the product as the enantiomers are separated. Many publications describe the SMB process, but they rarely address impurities (6, 7, 13). If an impurity is present in the racemic product, it can potentially be doubled after the separation because approximately 50% of the mass of the feed is removed. Therefore, it is important to know the fate of the impurity during the SMB separation.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here